A new therapy targeting toxic tau proteins in Alzheimer's disease.
Tau Oligomeric Complex 1 Antibody as a Novel Immuno-Gene Therapy for Tauopathy.
This study is exploring a new way to help people with Alzheimer's and similar conditions by using gene therapy to deliver a special antibody directly into brain cells, aiming to tackle the harmful tau proteins that cause damage.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11039023 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat tauopathies, including Alzheimer's disease, by using gene therapy to deliver a specific antibody that targets toxic tau proteins. The therapy aims to ensure that the antibody is delivered directly into neurons, where it can effectively neutralize harmful tau oligomers that contribute to neurodegeneration. By utilizing adeno-associated viruses (AAVs) for delivery, the research seeks to improve the specificity and efficiency of treatment compared to existing therapies. Patients may benefit from a targeted intervention that addresses the underlying causes of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies.
Not a fit: Patients with non-tauopathies or those not diagnosed with Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for Alzheimer's disease and related dementias by specifically targeting toxic tau proteins.
How similar studies have performed: Other research has shown promise in targeting tau proteins, but this specific approach using gene therapy is relatively novel.
Where this research is happening
East Lansing, United States
- Henry Ford Health + Michigan State University Health Sciences — East Lansing, United States (Active)
Researchers
- Principal investigator: Kanaan, Nicholas M — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Kanaan, Nicholas M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.